Stock Analysis
- United Kingdom
- /
- Pharma
- /
- AIM:HCM
HUTCHMED (China) First Half 2023 Earnings: EPS: US$0.20 (vs US$0.19 loss in 1H 2022)
HUTCHMED (China) (LON:HCM) First Half 2023 Results
Key Financial Results
- Revenue: US$532.9m (up 164% from 1H 2022).
- Net income: US$168.6m (up from US$162.9m loss in 1H 2022).
- Profit margin: 32% (up from net loss in 1H 2022).
- EPS: US$0.20 (up from US$0.19 loss in 1H 2022).
All figures shown in the chart above are for the trailing 12 month (TTM) period
HUTCHMED (China) Earnings Insights
Looking ahead, revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 6.7% growth forecast for the Pharmaceuticals industry in the United Kingdom.
Performance of the British Pharmaceuticals industry.
The company's share price is broadly unchanged from a week ago.
Risk Analysis
You should learn about the 1 warning sign we've spotted with HUTCHMED (China).
Valuation is complex, but we're helping make it simple.
Find out whether HUTCHMED (China) is potentially over or undervalued by checking out our comprehensive analysis, which includes fair value estimates, risks and warnings, dividends, insider transactions and financial health.
View the Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About AIM:HCM
HUTCHMED (China)
HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally.